Journal: Current Issues in Molecular Biology

Article Title: IGFBP5 Promotes Atherosclerosis in APOE −/− Mice Through Phenotypic Transformation of VSMCs

doi: 10.3390/cimb47070555

Figure Lengend Snippet: Overexpression of IGFBP5 does not influence food consumption by and the body weight of ApoE −/− mice. ( A ) IGFBP5 mRNA expression level in skeletal muscle of ApoE −/− mice at 10 weeks of experimental treatment ( n = 3). ( B ) Plasma IGFBP5 protein levels at 10 weeks of experimental treatment ( n = 3). ( C ) Weight change curve ( n = 15). ( D ) Comparison of average daily food intake during the entire experimental treatment among groups ( n = 15). Data are expressed as the mean ± SEM. * p < 0.05. NS means no significant difference.

Article Snippet: The primary antibody used in this experiment was a rabbit anti- IGFBP5 antibody (1:500, #55205-1-AP; Proteintech Group, Chicago, IL, USA).

Techniques: Over Expression, Expressing, Clinical Proteomics, Comparison

Journal: Current Issues in Molecular Biology

Article Title: IGFBP5 Promotes Atherosclerosis in APOE −/− Mice Through Phenotypic Transformation of VSMCs

doi: 10.3390/cimb47070555

Figure Lengend Snippet: Overexpression of IGFBP5 enhances the development of atherosclerotic plaques in ApoE −/− mice. Oil Red O staining of the aorta ( A ) and statistical quantification ( B ). ( C ) H&E staining (up panel) and Oil Red O staining (down panel) of cardiac outflow tract sections. Scale bar: 500 μm. ( D ) Statistical quantification of neutral lipids in the plaques of the cardiac outflow tract sections stained with Oil Red O ( n = 10). Data are expressed as the mean ± SEM. * p < 0.05. NS means no significant difference.

Article Snippet: The primary antibody used in this experiment was a rabbit anti- IGFBP5 antibody (1:500, #55205-1-AP; Proteintech Group, Chicago, IL, USA).

Techniques: Over Expression, Staining

Journal: Current Issues in Molecular Biology

Article Title: IGFBP5 Promotes Atherosclerosis in APOE −/− Mice Through Phenotypic Transformation of VSMCs

doi: 10.3390/cimb47070555

Figure Lengend Snippet: Effect of overexpression of IGFBP5 on blood lipid levels in ApoE −/− mice. Plasma was collected from each group of mice ( n = 15) at week 0, 4, 8, and 12 of treatment to measure total cholesterol (TC) ( A ), total triglycerides (TG) ( B ), low-density lipoprotein cholesterol (LDL-C) ( C ), and high-density lipoprotein cholesterol (HDL-C) ( D ) levels. Data are expressed as the mean ± SEM.

Article Snippet: The primary antibody used in this experiment was a rabbit anti- IGFBP5 antibody (1:500, #55205-1-AP; Proteintech Group, Chicago, IL, USA).

Techniques: Over Expression, Clinical Proteomics

Journal: Current Issues in Molecular Biology

Article Title: IGFBP5 Promotes Atherosclerosis in APOE −/− Mice Through Phenotypic Transformation of VSMCs

doi: 10.3390/cimb47070555

Figure Lengend Snippet: Transcriptome analysis of aortic tissues in ApoE −/− mice following overexpression of IGFBP5 . ( A , B ) Heatmap representing global gene expression in aortic tissues of AAV-GFP and AAV- IGFBP5 mice after 12 weeks of being fed a HFD ( n = 4).

Article Snippet: The primary antibody used in this experiment was a rabbit anti- IGFBP5 antibody (1:500, #55205-1-AP; Proteintech Group, Chicago, IL, USA).

Techniques: Over Expression, Gene Expression

Journal: Current Issues in Molecular Biology

Article Title: IGFBP5 Promotes Atherosclerosis in APOE −/− Mice Through Phenotypic Transformation of VSMCs

doi: 10.3390/cimb47070555

Figure Lengend Snippet: Gene Ontology analyses of the differentially expression genes in aortic tissues in ApoE −/− mice following overexpression of IGFBP5 . ( A ) Gene Ontology analyses of the differentially expression genes in aortic of AAV-GFP and AAV- IGFBP5 mice after 12 weeks of HFD ( n = 4). ( B ) GO analysis was performed based on three categories: biological process (BP), molecular function (MF), and cellular component (CC).

Article Snippet: The primary antibody used in this experiment was a rabbit anti- IGFBP5 antibody (1:500, #55205-1-AP; Proteintech Group, Chicago, IL, USA).

Techniques: Expressing, Over Expression

Journal: Current Issues in Molecular Biology

Article Title: IGFBP5 Promotes Atherosclerosis in APOE −/− Mice Through Phenotypic Transformation of VSMCs

doi: 10.3390/cimb47070555

Figure Lengend Snippet: Overexpression of IGFBP5 induces VSMCs to adopt a proliferative state. ( A ) Flow cytometric analysis of cell cycle distribution of immortalized mouse vascular smooth muscle cell line treated with different concentrations of IGFBP5 during proliferation ( n = 3). ( B ) Cell cycle distribution statistics ( n = 3). ( C ) The CCK-8 kit was used to detect the effect of different concentrations of IGFBP5 on VSMC proliferation for 24 h ( n = 5). ( D ) Effects of different concentrations of IGFBP5 on cell migration in cell scratch assays ( n = 3). ( E ) Statistics of relative distance of cell migration ( n = 3). ( F ) Real-time qPCR analysis of ACTA2 , MYH11 , TAGLN , CNN1 and KLF4 transcription expression in immortalized mouse vascular smooth muscle cells treated with different concentrations of IGFBP5 ( n = 3). GAPDH was used as a control. Data are expressed as the mean ± SEM. * p < 0.05.

Article Snippet: The primary antibody used in this experiment was a rabbit anti- IGFBP5 antibody (1:500, #55205-1-AP; Proteintech Group, Chicago, IL, USA).

Techniques: Over Expression, CCK-8 Assay, Migration, Expressing, Control

Journal: Discover Oncology

Article Title: Targeting miR-103a-3p/IGFBP5 axis: a potential therapeutic strategy for gastric cancer progression

doi: 10.1007/s12672-025-02390-w

Figure Lengend Snippet: IGFBP5 is a predicted target of miR-103a-3p. Heatmap a and volcano plot b of differentially expressed genes between untreated GC cells and miR-103a-3p-inhibited GC cells. N = 3 per group. c IGFBP5 expression levels between the NC and miR_IN groups (NC cells and miR inhibitor-transfected cells). d Gene Set Enrichment Analysis of differentially expressed genes in untreated GC cells and miR-103a-3p-inhibited GC cells. e Significant correlation is observed between miR-103a-3p and IGFBP5 expression based on TCGA-STAD. f Immunohistochemistry staining was used to determine the expression level of IGFBP5 in GC tissues and adjacent tissues. The mRNA g and protein h expression of IGFBP5 was detected in GES-1, MKN45, AGS, HGC-27 cells. *p < 0.05, **p < 0.01

Article Snippet: The commercial antibodies provided by Bioss included primary antibodies for IGFBP5 (1:1000) and β-actin (1:10,000), as well as a secondary antibody Goat Anti-Rabbit lgG (1:20,000).

Techniques: Expressing, Transfection, Immunohistochemistry, Staining

Journal: Discover Oncology

Article Title: Targeting miR-103a-3p/IGFBP5 axis: a potential therapeutic strategy for gastric cancer progression

doi: 10.1007/s12672-025-02390-w

Figure Lengend Snippet: miR-103a-3p targets IGFBP5 and inhibits its expression. a The expression of miR-103a-3p was quantified by qRT-PCR after transfection with mimic/inhibitor miR-103a-3p in AGS and MKN45 cells. b The binding sites of miR-103a-3p and IGFBP5 ( top: mutated target sequence of IGFBP5, middle: wt target DNA sequence of IGFBP5, bottom: miRNA sequence). c Luciferase reporter assays were conducted on AGS and MKN45 cells transfected with either miR-103a-3p mimic or control, along with wild-type or mutant IGFBP5 3ʹ-UTR constructs. *p < 0.05, **p < 0.01

Article Snippet: The commercial antibodies provided by Bioss included primary antibodies for IGFBP5 (1:1000) and β-actin (1:10,000), as well as a secondary antibody Goat Anti-Rabbit lgG (1:20,000).

Techniques: Expressing, Quantitative RT-PCR, Transfection, Binding Assay, Sequencing, Luciferase, Control, Mutagenesis, Construct

Journal: Discover Oncology

Article Title: Targeting miR-103a-3p/IGFBP5 axis: a potential therapeutic strategy for gastric cancer progression

doi: 10.1007/s12672-025-02390-w

Figure Lengend Snippet: miR-103a-3p promotes the mRNA and protein expression of GC cell via hampering IGFBP5. IGFBP5 mRNA a and protein b expression after oe IGFBP5 (overexpression of IGFBP5) transfection in AGS and MKN45 cells. c IGFBP5 mRNA expression was assessed in AGS and MKN45 cells using qRT-PCR under different treatment conditions. d western blot examined IGFBP5 protein expression in AGS and MKN45 cells with different treatments. *p < 0.05, **p < 0.01

Article Snippet: The commercial antibodies provided by Bioss included primary antibodies for IGFBP5 (1:1000) and β-actin (1:10,000), as well as a secondary antibody Goat Anti-Rabbit lgG (1:20,000).

Techniques: Expressing, Over Expression, Transfection, Quantitative RT-PCR, Western Blot

Journal: Discover Oncology

Article Title: Targeting miR-103a-3p/IGFBP5 axis: a potential therapeutic strategy for gastric cancer progression

doi: 10.1007/s12672-025-02390-w

Figure Lengend Snippet: miR-103a-3p facilitates the proliferation, migration, and invasion of GC cells by inhibiting IGFBP5. Proliferation capacity was assessed in AGS and MKN45 cells under different treatments using CCK8 a and colony formation b assays. Transwell assays were used to detect the invasion c and migration d abilities of AGS and MKN45 cells under varying treatments

Article Snippet: The commercial antibodies provided by Bioss included primary antibodies for IGFBP5 (1:1000) and β-actin (1:10,000), as well as a secondary antibody Goat Anti-Rabbit lgG (1:20,000).

Techniques: Migration